Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients
Recruiting · NCT06900374 · Interventional (participants receive a specific treatment) · Lead sponsor: Centre Oscar Lambret
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months. The study compares vaginal radiofrequency treatment with non-hormonal hydration therapy in a population of patients undergoing adjuvant hormonal therapy with aromatase inhibitors, with or without LHRH agonists, for breast cancer. Patients will be randomly assigned to one of two parallel treatment groups until the six-month assessment: The first group will receive the reference treatment, which consists of local hydration using a hyaluronic acid-based treatment applied three times a week. Additionally, investigators may incorporate supportive measures at their discretion, such as physiotherapy or vaginal dilators. The second group will receive the same reference treatment combined with vaginal radiofrequency therapy. This intervention consists of three sessions, each spaced 4 to 6 weeks apart.
Who can take part
Inclusion criteria
- Patient over 40 years
- Presenting disabling vaginal dryness symptoms despite well-administered local moisturizing treatment, attested by a vaginal dryness score ≥3
- Patient undergoing adjuvant treatment for breast cancer
- Patient treated with aromatase inhibitors +/- LHRH agonist for at least 3 months with a planned remaining duration of at least 12 months
- Patient affiliated to a social security organization
- Patient having signed the informed consent for the present study
Exclusion criteria
- Contraindications related to the radiofrequency technique:
- Ongoing urinary tract infection
- Pacemaker
- IUD intrauterine device
- Pregnancy
- Mucocutaneous disease with vulvovaginal localization: infection, sore, scleratrophic lichen, psoriasis, eczema, etc.
- Neurodegenerative disease with perineal involvement
- Current or recent treatment (within the last 12 months) with other physical methods: vaginal laser, photobiomodulation, PRP injection, hyaluronic acid injection or lipo-modeling.
- Pregnant or breast-feeding women
- Patients under guardianship or trusteeship.
Where it is running
1 location listed.
- Centre Oscar Lambret - Lille, France